CEO Shawn Leland (Elevation)
Elevation Oncology bags $65M to push failed Merrimack drug through PhII
Shawn Leland hadn’t even heard of NRG1 as an oncology target until he was sitting in a presentation at ESMO 2018 in Munich. Alex Drilon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
